Annual report pursuant to Section 13 and 15(d)

RFS Pharma, LLC Acquisition - Schedule of Purchase Price Consideration (Details)

v3.7.0.1
RFS Pharma, LLC Acquisition - Schedule of Purchase Price Consideration (Details)
$ in Thousands
Dec. 31, 2016
USD ($)
Business Combinations [Abstract]  
Purchased in-process research and development $ 184,966
Net book value of tangible assets acquired (183)
Goodwill 65,195
Deferred tax liability (65,195)
Total purchase price $ 184,783